

September 2024

one  
nucleus™

ON eNews



## Welcome to this month's eNews



**As the sun begins to set on the UK summer and many of our next generation of life science and investment leaders begin their next educational adventure, it feels from a variety of reports that the investment trends are positive. Some of the upbeat articles are linked below. Further afield, it is noticeable that Massachusetts announced jobs and investment growth, even highlighting three of their companies heading to IPO. One hopes the fair weather feel continues.**

Looking ahead to the autumn and beyond. You may have seen the recent [Events Update](#) from Alicia Gailliez setting out an exciting few months ahead, comprising BioWednesdays, Innovations Seminars, the Autumn Life Sciences Dinner, international activity and Special Interest Group meetings. Whether wanting to discuss the latest advances in Therapeutic Antibody Development, embracing efficiency to be sustainable, the One Health agenda, or simply to network with your next business partners and peers, One Nucleus feels like the place to be.

By way of an update on some of the One Nucleus initiatives. Participation at [Biotech Week Boston](#) will see a number of One Nucleus members travelling to the 'other Cambridge'. The UK Pitching Day we have organised with [BABCNE](#) and [UK Department of Business & Trade \(Boston\)](#) on 24 September will feature AisleVax, Carocell Bio, Cumulus Oncology, Drishti Discoveries, Expression Edits, Microbotica and PrecisionLife. The discounts at BioProcess International, World Medical Innovation Forum, and RESI-Boston are still available for those yet to book.

Excitement is also building for [Genesis 2024](#), this time with the new collaboration with Life Science Nation to deliver [RESI-London](#) alongside as a strategic partnership. The plans for Genesis are developing at pace, as you can see from the website. I'm already looking forward to writing the Genesis 2024 Review given the range of topics under discussion and expert speaker faculty who have agreed to contribute. You can check out the [Genesis Review 2023](#) as a reminder of the key messages to emerge. As mentioned above, there is growing optimism on the life science financing front, yet the more nuanced messaging would suggest the feel-good factor is not universally felt.

A particular recurring sentiment is that it remains extremely tough to raise seed and early-stage investment, whilst the deployed venture capital and Pharma deals focus on later-stage opportunities. This early-stage challenge has been a driver behind the One Nucleus collaboration with LSN/RESI as we seek to support our entrepreneurs and innovators in accessing globally available early-stage investment pools, perhaps from under rocks not traditionally explored by UK companies.

I am delighted to see below a selection of links to articles from our members and partners covering investment trends (BIA), UK regional investment and start-up data (Pioneer Group), Diagnostics Deals (PharmaVentures), and tackling AMR with GenAI and innovative R&D (Deloitte).

Finally, congratulations to **Richard Dickinson**, our Chief Technical Specialist, on his 16 year anniversary at One Nucleus. Richard has provided over 40 life science companies with invaluable facilities management and lab fit-out services in this period.



To stay informed of all One Nucleus updates, disseminate your company's news, or track the announcements from other members, you can make full use of our [website](#), [LinkedIn](#), or [X](#) pages. The [news stream](#) contains numerous updates from our community. Enjoy the read!

**Tony Jones, CEO, One Nucleus**



**Genesis 2024** Maximising Returns from Life Science Innovation

1 Wimpole Street, London  
4 December 2024

one nucleus™  
Strategic Partner  
LIFE SCIENCE NATION  
Connecting Products, Services & Capital

.....

### **Are You Targeting Your Advertising Spend for the Best Return?**

Whilst you can only sell to those who are looking to buy your service or product, engaging potential business partners intellectually in what you offer is a key first step. Alicia Gailliez, Business Development Manager, One Nucleus, considers the routes businesses use to reach and engage their target audience and outlines the merits and opportunities of being profiled in the forthcoming ON Helix 2024 Review as an example. [Read the article here.](#)

### **Has Biotech Investment Turned a Corner?**

Investment in the UK innovative life science and biotech industry showed strong growth between April and June in the face of continuing domestic and global economic uncertainty according to the BIA's UK biotech financing 2024 report. [Read more here.](#)

### **What's Hot in the Diagnostic Deal Space?**

Leveraging Non-Invasive Testing in CNS and Transplant Rejection: Ongoing Research and Early Pharma Partnerships Drive Diagnostic Innovations. Read PharmaVentures' [Dx Deal Review Q2 2024.](#)

### **What were the top 10 locations for UK Life Science investment in the UK in 1H 2024?**

The regular update from Pioneer illustrates how venture investment has been

deployed across the UK and which regions and centres dominate deal flow. Read the UK Life Sciences Market Update Q1 & Q2 2024 from [Pioneer here](#).

### The Role of Innovative R&D and GenAI in Helping to Tackle AMR

In 2019, the World Health Organisation (WHO) estimated that AMR was linked to around five million deaths and if this trend continues, annual AMR-related deaths could reach 10 million by 2050, with an estimated cost of \$100 trillion to the global economy. [Read the full article](#) by Deloitte.

### Don't Miss Your Opportunities at BIO-Europe - Deadlines Approaching!

Make the most of your presence at this leading industry trade show:

1. One Nucleus members receive a **12% discount** to [BIO-Europe](#) in Stockholm on 4-6 November. Unlock even more savings by booking by 13 September.
2. **Join our Enhanced Profiling Opportunity** from £250+VAT to be a part of our stand #192. Register your interest by 20 September.
3. **Sponsor** a page in our **ON Helix Review** from £500+VAT. Register your interest by 20 September.
4. Find out about other important [initatives at BIO-Europe](#) including **Merck's EMEA Advance Biotech Grant Program**, the **new partneringONE Enhanced Partnering Program** and the **Startup Spotlight** - deadline approaching 9 September!

.....

The banner features a blue background with a green vertical bar on the left. Text includes: 'LIVE WEBINAR', 'Streamlining Clinical Trial Review, Analysis, and Reporting with JMP Clinical', 'Address clinical trial challenges like efficiency, cost savings, and data management.', 'DATE 10 OCTOBER', 'TIME 14:00 CEST 13:00 BST', and the 'jmp STATISTICAL DISCOVERY' logo.

### One Nucleus Website Maintenance

One Nucleus is migrating to a new website /booking system. During this time we aim to keep you informed of progress, new developments and upcoming member benefits and events. The summer has been a busy period of preparation and planning as we build and test our new system to ensure as far as possible it is optimised for your engagement going forward.

Our website will be unavailable due to being transitioned from 09.30 on Monday 9 September. Online functions such as event booking, posting news jobs and events, updating information and new member applications will be unavailable. We will of course have manual processes in place for most functions. Please email [info@onenucleus.com](mailto:info@onenucleus.com) for assistance with these functions, or if you would like us to email you directly when our website is available again.

.....



[One Nucleus Events](#)

[Training Courses](#)

[Sector News](#)

Corporate Patron

AstraZeneca 

Corporate Sponsors





 **MSD**  
INVENTING FOR LIFE







Copyright © 2024

One Nucleus is an international membership organisation for life science and healthcare companies.

You have received this email newsletter as someone who has previously registered for One Nucleus eNews, attended its events or made contact with the organisation.